Back to Search Start Over

Dopamine transporter loss and clinical changes in MPTP-lesioned primates.

Authors :
Eberling JL
Bankiewicz KS
Pivirotto P
Bringas J
Chen K
Nowotnik DP
Steiner JP
Budinger TF
Jagust WJ
Source :
Brain research [Brain Res] 1999 Jun 19; Vol. 832 (1-2), pp. 184-7.
Publication Year :
1999

Abstract

Single photon emission computed tomography (SPECT) and the dopamine (DA) transporter tracer, 2 beta-carboxymethoxy-3 beta-(4-iodophenyl)tropane ([123I]beta-CIT), were used to determine DA transporter density in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-lesioned monkeys with varying degrees of parkinsonism. The clinical stage of parkinsonism corresponded to SPECT measures of striatal DA transporter density suggesting that more severe parkinsonism was associated with a greater degree of dopaminergic terminal degeneration. These findings are similar to those reported earlier using positron emission tomography (PET) and the DA metabolism tracer, 6-[18F]fluoro-L-m-tyrosine (FMT), indicating that both are good methods for evaluating nigrostriatal degeneration in MPTP primate models.<br /> (Copyright 1999 Elsevier Science B.V.)

Details

Language :
English
ISSN :
0006-8993
Volume :
832
Issue :
1-2
Database :
MEDLINE
Journal :
Brain research
Publication Type :
Academic Journal
Accession number :
10375668
Full Text :
https://doi.org/10.1016/s0006-8993(99)01491-2